Eloralintide
In clinical trialsAlso known as: LY3841136
Category: Weight & metabolic
Sold as:
Ameano Peptides: Eloralintide
Nexaph: Eloralintide
Investigational long-acting amylin receptor agonist from Eli Lilly. It reduces appetite through a different pathway from GLP-1 drugs.
What it's used for
- Obesity (investigational)
Dosing
- Typical dose
- Phase 2 trials used once-weekly doses that were increased gradually over several months. No approved dose exists.
- How often
- Once weekly
- Route
- Subcutaneous injection
- Cycle length
- Phase 2 ran about 48 weeks
Build a dosing plan for Eloralintide →
How to reconstitute and measure a dose → · About bacteriostatic water →
Possible side effects
- Nausea, vomiting and other GI effects, mostly during dose increases
- Fatigue
Important: Not approved. Anything sold outside clinical trials is unregulated, and purity cannot be assumed.